Results 1,021-1,040 of 3,998 for speaker:Michael Harty

Written Answers — Department of Health: Health Services Provision (26 Oct 2017)

Michael Harty: 153. To ask the Minister for Health when a person (details supplied) in County Clare will receive a reply from the HSE regarding a request for extra hours; and if he will make a statement on the matter. [45410/17]

Written Answers — Department of Employment Affairs and Social Protection: Telephone Support Allowance (7 Nov 2017)

Michael Harty: 82. To ask the Minister for Employment Affairs and Social Protection her plans to broaden the criteria for the new telephone support allowance by making it available to those persons in receipt of the living alone allowance or the fuel allowance; and if she will make a statement on the matter. [46610/17]

Written Answers — Department of Finance: Tracker Mortgage Examination Data (7 Nov 2017)

Michael Harty: 179. To ask the Minister for Finance the number of persons in County Clare that have been affected by the tracker mortgage scandal; and if he will make a statement on the matter. [46698/17]

Written Answers — Department of Finance: Interest Rates (7 Nov 2017)

Michael Harty: 239. To ask the Minister for Finance the reason why interests rates are high here compared to other EU countries; and if he will make a statement on the matter. [46699/17]

Written Answers — Department of Agriculture, Food and the Marine: Nitrates Usage (8 Nov 2017)

Michael Harty: 63. To ask the Minister for Agriculture, Food and the Marine the position regarding a product (details supplied) further to the decision by the European Parliament to back a full ban on glyphosate-based herbicides; and if he will make a statement on the matter. [46936/17]

Written Answers — Department of Health: Hospital Acquired Infections (8 Nov 2017)

Michael Harty: 153. To ask the Minister for Health the action he plans to take to combat the increased incidents of hospital acquired infections; and if he will make a statement on the matter. [47200/17]

Joint Oireachtas Committee on Health: Business of Joint Committee (8 Nov 2017)

Michael Harty: As we have quorum I wish to call the meeting to order. I propose that we go into private session to deal with housekeeping matters. Is that agreed? Agreed.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: The purpose of this morning's meeting is to engage with the HSE and the National Centre for Pharmacoeconomics, NCPE, regarding the processes involved in evaluating orphan drugs. On behalf of the committee, I welcome Mr. John Hennessy, national director of primary care, and Mr. Shaun Flanagan, chief pharmacist at the corporate pharmaceutical unit, from the HSE and, from the NCPE, Professor...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: I thank Mr. Hennessy. I call on Professor Barry to make his opening remarks.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: I thank Professor Barry. We will take members in groups of three, so I ask the witnesses to make a note of the various questions that are submitted. We will take Deputies Louise O'Reilly, Margaret Murphy O'Mahony and Billy Kelleher.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: I propose that we suspend the meeting briefly until we clarify the source of the sound.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: We will resume. Does Deputy Kelleher want to rephrase his question?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: Would Mr. Hennessy like to come in?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: Professor Barry stated the Food and Drug Administration, FDA, did not approve Translarna. Are we looking at the FDA or the European Medicines Agency, EMA? What is the view of the European Medicines Agency of Translarna?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: Why would one look to the FDA rather than the EMA?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: We have others who are yet to contribute.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: The Deputy may ask a supplementary question later. I must allow other members to contribute. I have another question. What is the manner of engagement with patient groups because such groups feel they are not being engaged with in a meaningful manner? What about representative organisations and specialists in the field where the drug applies, who feel they are not being engaged in a...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: Is there engagement where people are spoken to across a table?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: I thank Deputy Durkan. I invite Mr. Hennessy to lead off in replying to the questions.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: We are going to have to move on. There were some other questions. Perhaps Mr. Flanagan would like to go through those.